BACKGROUND: The Fibrosis-4 Index (FIB-4)non-invasively assesses fibrosis risk in chronic liver disease (CLD), but underdiagnosis limits FIB-4's application in primary care. OBJECTIVE: To evaluate the association of FIB-4 risk with hazard of severe liver outcomes in primary care patients with and without diagnosed CLD. DESIGN: Retrospective cohort study of primary care data from 2007 to 2018. PARTICIPANTS: Adult patients with qualifying aminotransferase and platelet count results were included and a single FIB-4 score was calculated for each patient using the first of these values. Patients with a CLD diagnosis or outcome prior to their FIB-4 score were excluded. MEASURES: FIB-4 advanced fibrosis risk categorization (low, indeterminate, and high) was the primary predictor variable. Patients were followed from FIB-4 score to a severe liver outcome, a composite of cirrhosis, liver transplantation, and hepatocellular carcinoma. We analyzed the association of FIB-4 risk categories with hazard risk of a severe liver outcome using stratified Cox regression models, stratifying patients by known CLD. KEY RESULTS: A total of 20,556 patients were followed for a mean 2,978 days (SD 1,201 days), and 4% of patients experienced a severe liver outcome. Of patients with low-, indeterminate-, and high-risk FIB-4 scores, 2%, 4%, and 20% suffered a severe liver outcome, respectively. In the overall adjusted model, high-risk FIB-4 scores were associated with hazard of severe liver disease (HR 6.64; 95% CI 5.58-7.90). High-risk FIB-4 scores were associated with severe liver outcomes for patients with known NAFLD (HR 7.32; 95% CI 3.44-15.58), other liver disease (HR 11.39; 95% CI 8.53-15.20), and no known CLD (HR 4.05; 95% CI 3.10-5.28). CONCLUSIONS: High-risk FIB-4 scores were strongly associated with risk of severe liver outcomes in patients with and without known CLD. Comprehensive FIB-4 application in primary care may signal silently advancing liver fibrosis.
BACKGROUND: The Fibrosis-4 Index (FIB-4)non-invasively assesses fibrosis risk in chronic liver disease (CLD), but underdiagnosis limits FIB-4's application in primary care. OBJECTIVE: To evaluate the association of FIB-4 risk with hazard of severe liver outcomes in primary care patients with and without diagnosed CLD. DESIGN: Retrospective cohort study of primary care data from 2007 to 2018. PARTICIPANTS: Adult patients with qualifying aminotransferase and platelet count results were included and a single FIB-4 score was calculated for each patient using the first of these values. Patients with a CLD diagnosis or outcome prior to their FIB-4 score were excluded. MEASURES: FIB-4 advanced fibrosis risk categorization (low, indeterminate, and high) was the primary predictor variable. Patients were followed from FIB-4 score to a severe liver outcome, a composite of cirrhosis, liver transplantation, and hepatocellular carcinoma. We analyzed the association of FIB-4 risk categories with hazard risk of a severe liver outcome using stratified Cox regression models, stratifying patients by known CLD. KEY RESULTS: A total of 20,556 patients were followed for a mean 2,978 days (SD 1,201 days), and 4% of patients experienced a severe liver outcome. Of patients with low-, indeterminate-, and high-risk FIB-4 scores, 2%, 4%, and 20% suffered a severe liver outcome, respectively. In the overall adjusted model, high-risk FIB-4 scores were associated with hazard of severe liver disease (HR 6.64; 95% CI 5.58-7.90). High-risk FIB-4 scores were associated with severe liver outcomes for patients with known NAFLD (HR 7.32; 95% CI 3.44-15.58), other liver disease (HR 11.39; 95% CI 8.53-15.20), and no known CLD (HR 4.05; 95% CI 3.10-5.28). CONCLUSIONS: High-risk FIB-4 scores were strongly associated with risk of severe liver outcomes in patients with and without known CLD. Comprehensive FIB-4 application in primary care may signal silently advancing liver fibrosis.
Authors: Rod S Taylor; Rebecca J Taylor; Sue Bayliss; Hannes Hagström; Patrik Nasr; Jorn M Schattenberg; Masatoshi Ishigami; Hidenori Toyoda; Vincent Wai-Sun Wong; Noam Peleg; Amir Shlomai; Giada Sebastiani; Yuya Seko; Neeraj Bhala; Zobair M Younossi; Quentin M Anstee; Stuart McPherson; Philip N Newsome Journal: Gastroenterology Date: 2020-02-04 Impact factor: 22.682
Authors: Andrew D Schreiner; Patrick D Mauldin; William P Moran; Valerie Durkalski-Mauldin; Jingwen Zhang; Samuel O Schumann; Marc E Heincelman; Justin Marsden; Don C Rockey Journal: Am J Med Sci Date: 2018-02-09 Impact factor: 2.378
Authors: Tait D Shanafelt; Lotte N Dyrbye; Christine Sinsky; Omar Hasan; Daniel Satele; Jeff Sloan; Colin P West Journal: Mayo Clin Proc Date: 2016-06-27 Impact factor: 7.616
Authors: Erin R Cleveland; Hongyan Ning; Miriam B Vos; Cora E Lewis; Mary E Rinella; John Jeffrey Carr; Donald M Lloyd-Jones; Lisa B VanWagner Journal: J Gen Intern Med Date: 2019-10-08 Impact factor: 5.128